WHAT IS KNOWN AND OBJECTIVES: mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. METHODS: Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. RESULTS AND DISCUSSION: A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. WHAT IS NEW AND CONCLUSION: The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague 2 Czech Republic

Zobrazit více v PubMed

Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20(10):1243-1249.

Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation. 1993;56(5):1202-1206.

Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83-95.

Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. Clin Pharmacokinet. 2009;48(8):489-516.

Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol. 1999;39(11):1155-1161.

Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19(5):e12751.

Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation. 2002;74(10):1477-1478.

Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003;43(10):1168-1176.

McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit. 2002;24(3):346-350.

Barshes NR, Goodpastor SE, Goss JA, DeBakey ME. Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation. 2003;76(11):1649-1650.

Capone D, Palmiero G, Gentile A, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr Drug Metab. 2007;8(4):379-381.

McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic drug-drug interactions between Letermovir and the Immunosuppressants cyclosporine, tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol. 2019;59(10):1331-1339.

O'Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transplant. 2013;19(4):463-465.

Cohen EE, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012;18(17):4785-4793.

Li RD, Guo WY, Fu ZR, Ding GS, Wang ZX, Fu H. A study about drug combination therapy of Schisandra sphenanthera extract and rapamycin in healthy subjects. Can J Physiol Pharm. 2012;90(7):941-945.

Fridell JA, Jain AK, Patel K, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther Drug Monit. 2003;25(1):117-119.

Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl. 2011;22(1):112-115.

Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005;5(3):595-603.

Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther. 2006;80(1):51-60.

Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48(5):694-703.

Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22(2):154-159.

Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther. 2001;70(5):425-430.

Zimmerman JJ, Lasseter KC, Lim HK, et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45(12):1368-1372.

Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25(3):701-707.

Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of Isavuconazole with the Immunosuppressants cyclosporine, mycophenolic acid, prednisolone, Sirolimus, and tacrolimus in healthy adults. Clin Pharm Drug Dev. 2017;6(1):76-85.

Tortorici MA, Parks V, Matschke K, Korth-Bradley J, Patat A. The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. Eur J Clin Pharmacol. 2013;69(4):835-842.

Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 2006;45(11):1135-1148.

Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70(3):247-254.

Wang R, Sun X, Deng YS, Qiu XW. Effects of MDR1 1236C > T-2677G > T-3435C > T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus. Xenobiotica. 2019;49(11):1373-1378.

Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014;28(5):590-597.

Lesche D, Sigurdardottir V, Setoud R, et al. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. Clin Transplant. 2015;29(12):1213-1220.

Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42(1):95-99.

Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38(10):3456-3458.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol. 2005;60(4):434-437.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol. 2005;61(1):35-38.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol. 2005;45(5):514-518.

Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother. 2002;36(6):981-985.

Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol. 2020;76(12):1667-1673.

Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant. 2000;14(2):97-109.

MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22(Suppl B):B101-B121.

Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69(1):48-56.

Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic drug monitoring of Everolimus: a consensus report. Ther Drug Monit. 2016;38(2):143-169.

Ter Heine R, van Erp NP, Guchelaar HJ, et al. A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Br J Clin Pharmacol. 2018;84(7):1575-1586.

Felipe C, Ferreira A, Bessa A, et al. Adequacy of initial Everolimus dose, with and without calcineurin inhibitors, in kidney transplant recipients. Ther Drug Monit. 2018;40(1):52-58.

Sima M, Bakhouche H, Hartinger J, Cikankova T, Slanar O. Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. Eur J Hosp Pharm. 2019;26(2):85-88.

Sima M, Vodicka M, Maresova V, Salek T, Cabala R, Slanar O. Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int J Clin Pharmacol. 2017;39(5):1095-1100.

Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374-384.